Takeda Pharmaceutical Company Limited Income Tax Expense Continuing Operations
Takeda Pharmaceutical Company Limited (TAK) reported Income Tax Expense Continuing Operations of JPY 66.94 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Income Tax
ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2025-06-25
| Period end | Income Tax Expense Continuing Operations 12 month | Income Tax Expense Continuing Operations 12 month as first filed |
|---|---|---|
| 2025-03-31 | 66.94B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | -91.41B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 58.05B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | 72.41B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | -9.94B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | -105.04B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | -7.47B JPY 20-F · filed 2021-06-29 | -14.12B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 30.50B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | 27.83B JPY 20-F · filed 2019-06-27 |